These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 33640794)

  • 1. A clinical trial of non-invasive imaging with an anti-HIV antibody labelled with copper-64 in people living with HIV and uninfected controls.
    McMahon JH; Zerbato JM; Lau JSY; Lange JL; Roche M; Tumpach C; Dantanarayana A; Rhodes A; Chang J; Rasmussen TA; Mackenzie CA; Alt K; Hagenauer M; Roney J; O'Bryan J; Carey A; McIntyre R; Beech P; O'Keefe GJ; Wichmann CW; Scott FE; Guo N; Lee ST; Liu Z; Caskey M; Nussenzweig MC; Donnelly PS; Egan G; Hagemeyer CE; Scott AM; Lewin SR
    EBioMedicine; 2021 Mar; 65():103252. PubMed ID: 33640794
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ex vivo sensitivity to broadly neutralizing antibodies and anti-CD4 antibody UB-421 of infectious viral isolates from people living with multidrug-resistant HIV.
    Rai MA; Blazkova J; Justement JS; Shi V; Kennedy BD; Manning MR; McLaughlin M; Sneller MC; Pau AK; Moir S; Chun TW
    EBioMedicine; 2024 Jun; 104():105151. PubMed ID: 38728839
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117.
    Caskey M; Klein F; Lorenzi JC; Seaman MS; West AP; Buckley N; Kremer G; Nogueira L; Braunschweig M; Scheid JF; Horwitz JA; Shimeliovich I; Ben-Avraham S; Witmer-Pack M; Platten M; Lehmann C; Burke LA; Hawthorne T; Gorelick RJ; Walker BD; Keler T; Gulick RM; Fätkenheuer G; Schlesinger SJ; Nussenzweig MC
    Nature; 2015 Jun; 522(7557):487-91. PubMed ID: 25855300
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of 3BNC117 and romidepsin on the HIV-1 reservoir in people taking suppressive antiretroviral therapy (ROADMAP): a randomised, open-label, phase 2A trial.
    Gruell H; Gunst JD; Cohen YZ; Pahus MH; Malin JJ; Platten M; Millard KG; Tolstrup M; Jones RB; Conce Alberto WD; Lorenzi JCC; Oliveira TY; Kümmerle T; Suárez I; Unson-O'Brien C; Nogueira L; Olesen R; Østergaard L; Nielsen H; Lehmann C; Nussenzweig MC; Fätkenheuer G; Klein F; Caskey M; Søgaard OS
    Lancet Microbe; 2022 Mar; 3(3):e203-e214. PubMed ID: 35544074
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early intervention with 3BNC117 and romidepsin at antiretroviral treatment initiation in people with HIV-1: a phase 1b/2a, randomized trial.
    Gunst JD; Pahus MH; Rosás-Umbert M; Lu IN; Benfield T; Nielsen H; Johansen IS; Mohey R; Østergaard L; Klastrup V; Khan M; Schleimann MH; Olesen R; Støvring H; Denton PW; Kinloch NN; Copertino DC; Ward AR; Alberto WDC; Nielsen SD; Puertas MC; Ramos V; Reeves JD; Petropoulos CJ; Martinez-Picado J; Brumme ZL; Jones RB; Fox J; Tolstrup M; Nussenzweig MC; Caskey M; Fidler S; Søgaard OS
    Nat Med; 2022 Nov; 28(11):2424-2435. PubMed ID: 36253609
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption.
    Scheid JF; Horwitz JA; Bar-On Y; Kreider EF; Lu CL; Lorenzi JC; Feldmann A; Braunschweig M; Nogueira L; Oliveira T; Shimeliovich I; Patel R; Burke L; Cohen YZ; Hadrigan S; Settler A; Witmer-Pack M; West AP; Juelg B; Keler T; Hawthorne T; Zingman B; Gulick RM; Pfeifer N; Learn GH; Seaman MS; Bjorkman PJ; Klein F; Schlesinger SJ; Walker BD; Hahn BH; Nussenzweig MC; Caskey M
    Nature; 2016 Jul; 535(7613):556-60. PubMed ID: 27338952
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety, tolerability, pharmacokinetics, and immunological activity of dual-combinations and triple-combinations of anti-HIV monoclonal antibodies PGT121, PGDM1400, 10-1074, and VRC07-523LS administered intravenously to HIV-uninfected adults: a phase 1 randomised trial.
    Sobieszczyk ME; Mannheimer S; Paez CA; Yu C; Gamble T; Theodore DA; Chege W; Yacovone M; Hanscom B; Heptinstall J; Seaton KE; Zhang L; Miner MD; Eaton A; Weiner JA; Mayer K; Kalams S; Stephenson K; Julg B; Caskey M; Nussenzweig M; Gama L; Barouch DH; Ackerman ME; Tomaras GD; Huang Y; Montefiori D;
    Lancet HIV; 2023 Oct; 10(10):e653-e662. PubMed ID: 37802566
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety, pharmacokinetics, and immunogenicity of the combination of the broadly neutralizing anti-HIV-1 antibodies 3BNC117 and 10-1074 in healthy adults: A randomized, phase 1 study.
    Cohen YZ; Butler AL; Millard K; Witmer-Pack M; Levin R; Unson-O'Brien C; Patel R; Shimeliovich I; Lorenzi JCC; Horowitz J; Walsh SR; Lin S; Weiner JA; Tse A; Sato A; Bennett C; Mayer B; Seaton KE; Yates NL; Baden LR; deCamp AC; Ackerman ME; Seaman MS; Tomaras GD; Nussenzweig MC; Caskey M
    PLoS One; 2019; 14(8):e0219142. PubMed ID: 31393868
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cocrystal Structures of Antibody N60-i3 and Antibody JR4 in Complex with gp120 Define More Cluster A Epitopes Involved in Effective Antibody-Dependent Effector Function against HIV-1.
    Gohain N; Tolbert WD; Acharya P; Yu L; Liu T; Zhao P; Orlandi C; Visciano ML; Kamin-Lewis R; Sajadi MM; Martin L; Robinson JE; Kwong PD; DeVico AL; Ray K; Lewis GK; Pazgier M
    J Virol; 2015 Sep; 89(17):8840-54. PubMed ID: 26085162
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BREATHER (PENTA 16) short-cycle therapy (SCT) (5 days on/2 days off) in young people with chronic human immunodeficiency virus infection: an open, randomised, parallel-group Phase II/III trial.
    Butler K; Inshaw J; Ford D; Bernays S; Scott K; Kenny J; Klein N; Turkova A; Harper L; Nastouli E; Paparini S; Choudhury R; Rhodes T; Babiker A; Gibb D
    Health Technol Assess; 2016 Jun; 20(49):1-108. PubMed ID: 27377073
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polyfunctional Fc Dependent Activity of Antibodies to Native Trimeric Envelope in HIV Elite Controllers.
    Kant S; Zhang N; Barbé A; Routy JP; Tremblay C; Thomas R; Szabo J; Côté P; Trottier B; LeBlanc R; Rouleau D; Harris M; Dupuy FP; Bernard NF
    Front Immunol; 2020; 11():583820. PubMed ID: 33101312
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Broadly neutralizing antibody epitopes on HIV-1 particles are exposed after virus interaction with host cells.
    Rao PG; Lambert GS; Upadhyay C
    J Virol; 2023 Sep; 97(9):e0071023. PubMed ID: 37681958
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety, pharmacokinetics and antiviral activity of PGT121, a broadly neutralizing monoclonal antibody against HIV-1: a randomized, placebo-controlled, phase 1 clinical trial.
    Stephenson KE; Julg B; Tan CS; Zash R; Walsh SR; Rolle CP; Monczor AN; Lupo S; Gelderblom HC; Ansel JL; Kanjilal DG; Maxfield LF; Nkolola J; Borducchi EN; Abbink P; Liu J; Peter L; Chandrashekar A; Nityanandam R; Lin Z; Setaro A; Sapiente J; Chen Z; Sunner L; Cassidy T; Bennett C; Sato A; Mayer B; Perelson AS; deCamp A; Priddy FH; Wagh K; Giorgi EE; Yates NL; Arduino RC; DeJesus E; Tomaras GD; Seaman MS; Korber B; Barouch DH
    Nat Med; 2021 Oct; 27(10):1718-1724. PubMed ID: 34621054
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural definition of an antibody-dependent cellular cytotoxicity response implicated in reduced risk for HIV-1 infection.
    Acharya P; Tolbert WD; Gohain N; Wu X; Yu L; Liu T; Huang W; Huang CC; Kwon YD; Louder RK; Luongo TS; McLellan JS; Pancera M; Yang Y; Zhang B; Flinko R; Foulke JS; Sajadi MM; Kamin-Lewis R; Robinson JE; Martin L; Kwong PD; Guan Y; DeVico AL; Lewis GK; Pazgier M
    J Virol; 2014 Nov; 88(21):12895-906. PubMed ID: 25165110
    [TBL] [Abstract][Full Text] [Related]  

  • 15. First-in-human immunoPET imaging of HIV-1 infection using
    Beckford-Vera DR; Flavell RR; Seo Y; Martinez-Ortiz E; Aslam M; Thanh C; Fehrman E; Pardons M; Kumar S; Deitchman AN; Ravanfar V; Schulte B; Wu IK; Pan T; Reeves JD; Nixon CC; Iyer NS; Torres L; Munter SE; Hyunh T; Petropoulos CJ; Hoh R; Franc BL; Gama L; Koup RA; Mascola JR; Chomont N; Deeks SG; VanBrocklin HF; Henrich TJ
    Nat Commun; 2022 Mar; 13(1):1219. PubMed ID: 35264559
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Viremic HIV infected individuals with high CD4 T cells and functional envelope proteins show anti-gp41 antibodies with unique specificity and function.
    Curriu M; Fausther-Bovendo H; Pernas M; Massanella M; Carrillo J; Cabrera C; López-Galíndez C; Clotet B; Debré P; Vieillard V; Blanco J
    PLoS One; 2012; 7(2):e30330. PubMed ID: 22312424
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Co-receptor Binding Site Antibodies Enable CD4-Mimetics to Expose Conserved Anti-cluster A ADCC Epitopes on HIV-1 Envelope Glycoproteins.
    Richard J; Pacheco B; Gohain N; Veillette M; Ding S; Alsahafi N; Tolbert WD; Prévost J; Chapleau JP; Coutu M; Jia M; Brassard N; Park J; Courter JR; Melillo B; Martin L; Tremblay C; Hahn BH; Kaufmann DE; Wu X; Smith AB; Sodroski J; Pazgier M; Finzi A
    EBioMedicine; 2016 Oct; 12():208-218. PubMed ID: 27633463
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of Broadly Neutralizing Antibody Sensitivity by Genotyping and Phenotyping for Qualifying Participants to HIV Clinical Trials.
    Moldt B; Parvangada A; Martin R; Pace C; Balakrishnan M; Thomsen ND; E Collins S; Kuster H; Braun DL; Günthard HF; Geleziunas R; Callebaut C
    J Acquir Immune Defic Syndr; 2021 Sep; 88(1):61-69. PubMed ID: 34397744
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibody-Dependent Cellular Cytotoxicity-Competent Antibodies against HIV-1-Infected Cells in Plasma from HIV-Infected Subjects.
    Dupuy FP; Kant S; Barbé A; Routy JP; Bruneau J; Lebouché B; Tremblay C; Pazgier M; Finzi A; Bernard NF
    mBio; 2019 Dec; 10(6):. PubMed ID: 31848282
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterizing the Relationship Between Neutralization Sensitivity and
    Wilson A; Shakhtour L; Ward A; Ren Y; Recarey M; Stevenson E; Korom M; Kovacs C; Benko E; Jones RB; Lynch RM
    Front Immunol; 2021; 12():710327. PubMed ID: 34603284
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.